Yazar "Artac, M." seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Correlates of benefit from induction chemotherapy before radiotherapy in non-small cell lung cancer (NSCLC): A meta-analytical approach with meta-regression analysis(AMER SOC CLINICAL ONCOLOGY, 2008) Bozcuk, H. S.; Ozdogan, M.; Artac, M.; Yildiz, M.[Abstract not Available]Öğe Correlates of Benefit From Neoadjuvant Chemotherapy Before Radiotherapy in Non-small Cell Lung Cancer: A Meta-Analytical Approach With Meta-Regression Analysis(Zerbinis Medical Publ, 2010) Bozcuk, H.; Artac, M.; Özdoğan, M.Purpose: Induction chemotherapy before radiotherapy, although inferior to concomitant chemoradiotherapy, is still used in clinical practice, and improves survival compared to radiotherapy alone in unresectable non-small cell lung cancer (NSCLC). In this setting, we assessed the predictors of benefit from neoadjuvant chemotherapy before radiotherapy. Methods: Searches were made for randomized clinical trials (RCTs) that compared neoadjuvant chemotherapy with no treatment, administered before definitive radiotherapy. Relative risk (RR) was employed to define the risk of death at 2 and 3 years. Additionally, meta-regression analysis was conducted to explain heterogeneity. Results: Thirteen RCTs to date, encompassing 2776 patients, were identified. In this updated meta-analysis, neoadjuvant chemotherapy significantly reduced the risk of death, both at 2 and 3 years (RR = 0.91 and 0.94, respectively both p < 0.001). Additionally, time to radiotherapy was inversely associated with the benefit from neoadjuvant chemotherapy at 2 (t = 2.20,p = 0.050) and 3 years (t = 1.84, p = 0.093). Conclusion: This meta-analysis confirms the importance of neoadjuvant chemotherapy before radiotherapy and highlights the importance of shorter time to radiotherapy to maximize NSCLC patients 'survival.Öğe An encouraging chemotherapy regimen in progressive small cell lung cancer - Irinotecan and Ifosfamide: an experience from single center(PERGAMON-ELSEVIER SCIENCE LTD, 2009) Bozcuk, H.; Mutlu, H.; Artac, M.; Ozdogan, M.; Coskun, H. S.; Kargi, A.; Uysal, M.[Abstract not Available]Öğe Impressive survival data with semimetronomic oral chemotherapy with old agents in heavily treated metastatic breast cancer patients(AMER SOC CLINICAL ONCOLOGY, 2009) Mutlu, H.; Bozcuk, H.; Ozdogan, M.; Artac, M.; Coskun, H. S.; Kargi, A.; Uysal, M.[Abstract not Available]Öğe Maintenance semi-metronomic oral cyclophospahamide and oral etoposide regimen in extensive stage small cell lung cancer (SCLC) patients after responding first line treatment(PERGAMON-ELSEVIER SCIENCE LTD, 2009) Ozdogan, M.; Kargi, A.; Artac, M.; Bozcuk, H.; Boruban, M. C.; Coskun, H. S.; Mutlu, H.[Abstract not Available]Öğe Radiotherapy-induced Hypopituitarism in Nasopharyngeal Carcinoma: the Tip of an Iceberg(JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH, 2015) Ipekci, S. H.; Cakir, M.; Kiyici, A.; Koc, O.; Artac, M.Background: Radiation-induced hypopituitarism is an important late complication of cranial radiotherapy in children and adults. The purpose of this cross-sectional study was to evaluate the effects of radiotherapy on pituitary function in adult nasopharyngeal carcinoma patients. Methods: Pituitary function was evaluated in 30 patients after cranial radiotherapy for nasopharyngeal carcinoma. Somatotroph and corticotroph axes were assessed by insulin tolerance test while gonadotroph and thyroid axes were evaluated by basal pituitary and end organ hormone levels at 10-133 months after radiotherapy. Results: At least one hormonal disorder was observed in 28 (93%) patients after radiotherapy. 26 (87%) patients had one or more anterior pituitary hormone deficiencies. The rates of pituitary hormone deficiencies were 77% for growth hormone, followed by adrenocorticotropic hormone (73%), thyroid-stimulating hormone (27%) and gonadotropins (7%). Hyperprolactinemia was present in 13 (43%) patients. Conclusions: Radiation-induced hypopituitarism is more common than expected in patients with nasopharyngeal carcinoma.